Business
Avacta Announces AVA6000 Poster at AACR
Avacta Announces AVA6000 Poster at AACR.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n\n6 March 2024\n \nAvacta Group plc\n \n(\"Avacta\" or \"the Group\" or \"the Company\")\n \nUpdated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024\n \nAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below. \nPresentation details\nTitle: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors\nSession Title: First-in-Human Phase I Clinical Trials 2\nSession Date and Time: Tuesday 9 April 2024 9:00 AM - 12:30 PM\nLocation: San Diego Convention Center, San Diego CA USA\nAbstract Presentation Number: CT188\nFirst Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust\n \n \n-Ends-\n \n \nFor further information from Avacta Group plc, please contact:\n \n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\nMichael Vinegrad, Group Communications Director\n \n\n\nTel: +44 (0) 1904 21 7070\nwww.avacta.com\n\n\n\n\nStifel Nicolaus Europe Limited (Nomad and Joint Broker)\nNicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland\n \n\n\nTel: +44 (0) 207 710 7600\nwww.stifel.com\n\n\n\n\nPeel Hunt (Joint Broker)\nJames Steel / Chris Golden / Patrick Birkholm\n\n\nTel: +44 (0) 207 418 8900\nwww.peelhunt.com\n \n\n\n\n\nICR Consilium (Media and IR)\nMary-Jane Elliott / Jessica Hodgson / Sukaina Virji\n\n\[email protected]\n\n\n\n\n \n \n \nAbout AVA6000\nAVA6000, Avacta Therapeutics' lead oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moie...